)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Hua Medicine
Hua Medicine (2552) investor relations material
Hua Medicine H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary21 Aug, 2026
Executive summary
Achieved rapid commercialization progress with HuaTangNing, driving a 74% year-over-year revenue increase to RMB378.9 million for H1 2026, supported by a 73% increase in sales volume to 3,055,000 packs and expanded commercialization team.
Gross profit rose 99% year-over-year to RMB234.3 million, with gross margin improving to 61.8% from 54.2% due to expanded production scale and efficiency.
Net loss narrowed significantly to RMB30.2 million, excluding the prior year’s one-off Bayer contract termination gain, reflecting improved operational efficiency.
Cash balances remained strong at RMB1,072.9 million as of June 30, 2026, supporting ongoing R&D and commercialization initiatives.
Patent life for dorzagliatin extended to April 2034, with new product launches in Hong Kong and Macao and expansion plans for Southeast Asia.
Financial highlights
Revenue rose 74% year-over-year to RMB378.9 million, driven by a 73% increase in HuaTangNing sales volume.
Gross profit increased 99% to RMB234.3 million; gross margin improved by 7.6 percentage points to 61.8%.
Selling expenses rose 98% to RMB126.9 million, mainly due to team expansion and increased marketing activities; selling expense ratio at 33.5%.
R&D expenses were RMB66.8 million, up slightly from RMB65.8 million, reflecting ongoing clinical trials and post-marketing studies.
Net loss for the period was RMB30.2 million, with adjusted loss narrowing by RMB29.4 million year-over-year (excluding 2025's one-off gain).
Outlook and guidance
Targeting continued strong sales growth and geographic expansion, leveraging AI tools and commercialization capabilities.
Expecting to achieve profitability in 2027, with ongoing investment in pipeline expansion and new indications for dorzagliatin.
U.S. Phase Ib MAD trial for second-generation GKA to complete in H2 2026, with plans for global partnerships.
Employee incentive-linked revenue targets set at RMB900 million for 2026.
NDA submission for dorzagliatin/metformin FDC planned for 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hua Medicine
- Pivotal trials advance, but COVID-19 may delay data review and results.2552
H2 2019 - Bayer partnership backs dorzagliatin commercialization as pivotal trials move toward an H1 2021 NDA filing.2552H1 2020
- Record profit and 93% revenue growth in 2025, with dorzagliatin sales and patent exclusivity extended.2552H2 2025
- Profit soared on 112% revenue growth, Bayer income, and margin gains in H1 2025.2552H1 2025
- NRDL inclusion drove 46% revenue growth but led to lower margins and higher losses.2552H1 2024
- Dorzagliatin achieves diabetes remission and restores glucose homeostasis, redefining T2D care.2552BIO International 2024 San Diego Presentation
- Revenue up 234% in 2024 on NRDL inclusion; full commercialization and global expansion underway.2552H2 2024
Next Hua Medicine earnings date
H2 202626 Mar, 2027
Hua Medicine
Next Hua Medicine earnings date
H2 202626 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Hua Medicine is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of metabolic diseases. The company specializes in drug candidates targeting type 2 diabetes and related conditions, leveraging internal research and clinical development capabilities. Hua Medicine conducts both domestic and international clinical trials and collaborates with academic and industry partners to advance its pipeline. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.